Lymphoma & CLL Subtypes

Treatment landscape for mantle cell lymphoma: An update

The virtual Lymphoma Hub Satellite Symposium on the sequencing of therapies in high-risk relapsed/refractory (R/R) lymphoma and chronic...

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Tycel Phillips, University of...

What novel targeted therapies are currently under investigation for R/R CLL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne,...

The management of toxicities associated with targeted agents in CLL

The Lymphoma Hub is looking forward to hosting a virtual satellite symposium on the sequencing of therapies in high-risk...

EMA grants marketing authorization to duvelisib monotherapy for R/R CLL or FL

On June 9, 2021, it was announced that, in May 2021, the European Medicines Agency (EMA) granted marketing authorization...

Targeted agents for patients with follicular lymphoma

The virtual Lymphoma Hub Satellite Symposium will take place on Friday, June 18, 2021, at the 16th International Conference on Malignant Lymphoma...

BRUIN trial: Phase I/II of pirtobrutinib, a novel, reversible BTK inhibitor for relapsed B-cell malignancies

When treating B cell-malignancies, covalent inhibitors correspond to the most frequently...

Positive effect on HRQoL and symptom severity with liso-cel in patients with R/R LBCL

Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for the...